AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10847577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioptic telescopes and training
Number of subjects: 25
Study 10847577 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with telescopic lenses
Number of subjects: 25
Study 10847577 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving-related skills training
Number of subjects: 25
Study 10847577 — intervention group
Group type: COMPARATOR
Intervention: Telescopic lenses without training
Number of subjects: 25
Study 9413107 — intervention group
Group type: EXPERIMENTAL
Intervention: Two primary doses of DTaP
Number of subjects: 0
Study 9413107 — intervention group
Group type: COMPARATOR
Intervention: Three primary doses of DTaP
Number of subjects: 0
Study 9413107 — intervention group
Group type: EXPERIMENTAL
Intervention: Two primary doses of DTaP followed by a booster
Number of subjects: 0
Study 9413107 — intervention group
Group type: COMPARATOR
Intervention: Three primary doses of DTaP followed by a booster
Number of subjects: 0
Study 8383638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 30
Study 8383638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3758146 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE 1 mg intranasally
Number of subjects: 9
Study 3758146 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE 0.5 mg intramuscularly
Number of subjects: 9
Study 3758146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasally and i.m.)
Number of subjects: 9
Study 28722271 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 to 1.8 mg over 24 weeks)
Number of subjects: 15
Study 28722271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 15
Study 27535438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 32
Study 27535438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 32
Study 25014996 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuan Bai Cheng Qi formula
Number of subjects: 244
Study 25014996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 21256606 — intervention group
Group type: COMPARATOR
Intervention: Control saline (n=55)
Number of subjects: 213
Study 21256606 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 50 μg (n=54)
Number of subjects: 213
Study 21256606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 4 mg (n=54)
Number of subjects: 213
Study 21256606 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine-nicorandil combination (n=50)
Number of subjects: 213
Study 20392970 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA interference screws
Number of subjects: 77
Study 20392970 — intervention group
Group type: COMPARATOR
Intervention: Metal interference screws
Number of subjects: 77
Study 18721643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoria
Number of subjects: 72
Study 18721643 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital discord
Number of subjects: 72
Study 18721643 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticality bias
Number of subjects: 72
Study 16567820 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM intervention
Number of subjects: 119
Study 14531555 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA) administration for fluorescence-guided resections
Number of subjects: 0
Study 14531555 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11041588 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee replacement (UKR)
Number of subjects: 43
Study 8613538 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil capsules (1.5-1.8 grams DHA/day)
Number of subjects: 41
Study 8613538 — intervention group
Group type: COMPARATOR
Intervention: Control oil capsules (97% soybean oil + 3% fish oil)
Number of subjects: 41
Study 1486515 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal safety program taught by parents
Number of subjects: 172
Study 1486515 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal safety program taught by teachers
Number of subjects: 172
Study 1486515 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal safety program taught by both teachers and parents
Number of subjects: 172
Study 1486515 — intervention group
Group type: COMPARATOR
Intervention: General safety control program
Number of subjects: 172
Study 3882681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 30 mg
Number of subjects: 8
Study 3882681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 8
Study 3882681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 75 mg
Number of subjects: 8
Study 3882681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31995223 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation
Number of subjects: 46
Study 29368635 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glycaemic control (4-7 mmol/L; 72-126 mg/dl)
Number of subjects: 20
Study 29368635 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycaemic control (<10 mmol/L; 180 mg/dl)
Number of subjects: 20
Study 27031544 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 0
Study 27031544 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 0
Study 26525102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation for 6 weeks
Number of subjects: 191
Study 26525102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 191
Study 26525102 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in PLA2G4A and PLA2G6 genes
Number of subjects: 191
Study 23674289 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 174
Study 23674289 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD)
Number of subjects: 174
Study 19944453 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VB) alone
Number of subjects: 87
Study 18413554 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg
Number of subjects: 973
Study 18413554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg
Number of subjects: 973
Study 18413554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 973
Study 16792171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting forceps
Number of subjects: 100
Study 16792171 — intervention group
Group type: COMPARATOR
Intervention: Non-cutting forceps
Number of subjects: 100
Study 15189665 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 401
Study 15189665 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 401
Study 10601051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal long chain triglyceride (LCT) infusion
Number of subjects: 9
Study 10601051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal medium chain triglyceride (MCT) infusion
Number of subjects: 9
Study 10601051 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 9
Study 9175688 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 186
Study 9175688 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 186
Study 9175688 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative workup and diagnostic laparoscopy
Number of subjects: 186
Study 1550081 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification chemotherapy
Number of subjects: 192
Study 1550081 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance therapy
Number of subjects: 192
Study 3516395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (3 g/m2 every 12 hours for 6 days)
Number of subjects: 48
Study 3516395 — intervention group
Group type: COMPARATOR
Intervention: Amsacrine (75 mg/m2 daily for 7 days)
Number of subjects: 48
Study 30252548 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blistering technique
Number of subjects: 30
Study 30252548 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini punch technique
Number of subjects: 30
Study 30252548 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair follicle technique
Number of subjects: 30
Study 30252548 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques (suction blistering, mini punch, hair follicle)
Number of subjects: 30
Study 27357833 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter
Number of subjects: 494
Study 27357833 — intervention group
Group type: COMPARATOR
Intervention: Facebook
Number of subjects: 494
Study 25448996 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Heidelberg Retina Tomograph (HRT) parameters
Number of subjects: 489
Study 23567070 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol treatment
Number of subjects: 52
Study 23567070 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 52
Study 21174107 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery (LS)
Number of subjects: 1033
Study 19210140 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 BID
Number of subjects: 372
Study 19210140 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 QD
Number of subjects: 372
Study 19210140 — intervention group
Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 372
Study 16887443 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg/kg/day for 2 weeks, with weaning over the subsequent 2 weeks)
Number of subjects: 171
Study 16887443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 15534844 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ST monitoring with synthesized 12-lead ECG and telephone transmission to the target hospital.
Number of subjects: 5
Study 15534844 — intervention group
Group type: COMPARATOR
Intervention: Control group using only ECGs recorded after hospital arrival.
Number of subjects: 5
Study 11705719 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 22
Study 11705719 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 22
Study 9024171 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen coadministered with isoniazid (8 am dose)
Number of subjects: 10
Study 9024171 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen given 12 hours after isoniazid dose
Number of subjects: 10
Study 9024171 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with isoniazid for fast acetylators
Number of subjects: 10
Study 9024171 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with isoniazid for slow acetylators
Number of subjects: 10
Study 8155010 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (30 or 283 mg/d)
Number of subjects: 3021
Study 8155010 — intervention group
Group type: EXPERIMENTAL
Intervention: History and electrocardiogram assessment
Number of subjects: 3021
Study 3351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable lap computer (PLC)
Number of subjects: 12
Study 3351376 — intervention group
Group type: COMPARATOR
Intervention: Conventional ward terminals
Number of subjects: 12
Study 31362299 — intervention group
Group type: COMPARATOR
Intervention: High-Flux Hemodialysis (HF-HD)
Number of subjects: 16
Study 31362299 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (olHDF)
Number of subjects: 16
Study 31362299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Retention-Onset Hemodialysis (HRO-HD)
Number of subjects: 16
Study 30282670 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week for 24 weeks, then 25 mg/week)
Number of subjects: 90
Study 30282670 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 90
Study 30282670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27027523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (IVR)
Number of subjects: 60
Study 27027523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (IVA)
Number of subjects: 60
Study 27027523 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 60
Study 24716478 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week IPV prevention intervention using a men's discussion group format
Number of subjects: 12
Study 24164001 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program based on Gibson's model (weeks 1, 4, and 8)
Number of subjects: 60
Study 24164001 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 60
Study 21940397 — intervention group
Group type: COMPARATOR
Intervention: McGrath laryngoscope
Number of subjects: 48
Study 21940397 — intervention group
Group type: EXPERIMENTAL
Intervention: APA with Difficult Airway Blade (DAB)
Number of subjects: 48
Study 21940397 — intervention group
Group type: EXPERIMENTAL
Intervention: APA with DAB
Number of subjects: 48
Study 18196524 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin (SV) tablet formulation
Number of subjects: 12
Study 17075122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.5 mg/m2 (arm A)
Number of subjects: 155
Study 17075122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 plus docetaxel 75 mg/m2 (arm B)
Number of subjects: 155
Study 14504681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 10955391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 0
Study 10955391 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (FK 506)
Number of subjects: 0
Study 8612412 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.75 mg/kg)
Number of subjects: 32
Study 8612412 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.35 mg/kg)
Number of subjects: 32
Study 8612412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1329937 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable oestrogen dosage regimen
Number of subjects: 21
Study 1329937 — intervention group
Group type: COMPARATOR
Intervention: Fixed 1 mg oestrogen dosage regimen
Number of subjects: 21
Study 1329937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed 2 mg oestrogen dosage regimen
Number of subjects: 21
Study 1329937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed 4 mg oestrogen dosage regimen
Number of subjects: 21
Study 6574611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortnightly sodium fluoride rinsing and topical painting with ferric aluminum fluoride solution
Number of subjects: 0
Study 6574611 — intervention group
Group type: COMPARATOR
Intervention: Fortnightly sodium fluoride rinsing and topical painting with neutral 0.2% sodium fluoride solution
Number of subjects: 0
Study 29143462 — intervention group
Group type: EXPERIMENTAL
Intervention: ABG/melatonin composite graft
Number of subjects: 26
Study 29143462 — intervention group
Group type: COMPARATOR
Intervention: ABG (control group)
Number of subjects: 26
Study 28826168 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional resistance training (12-week period, 24 sessions, 2 days per week)
Number of subjects: 19
Study 27922448 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-facilitated cCBT
Number of subjects: 369
Study 27922448 — intervention group
Group type: COMPARATOR
Intervention: Minimally supported cCBT
Number of subjects: 369
Study 24270198 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management by cytology every 6 months in primary care
Number of subjects: 171
Study 24270198 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HPV-18
Number of subjects: 171
Study 24270198 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HPV-16 and/or HPV-18 at recruitment
Number of subjects: 171
Study 24270198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HPV-16/HPV-18 test
Number of subjects: 171
Study 19249429 — intervention group
Group type: EXPERIMENTAL
Intervention: clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD)
Number of subjects: 110
Study 19249429 — intervention group
Group type: EXPERIMENTAL
Intervention: prasugrel 60 mg LD/10 mg MD
Number of subjects: 110
Study 19249429 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 110
Study 15097437 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.3 g/kg/day for 7 days)
Number of subjects: 128
Study 15097437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 11556508 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine potassium iodide (IKI) irrigation for 5 min after cleaning and shaping
Number of subjects: 40
Study 11556508 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide filling for 10-14 days after cleaning and shaping
Number of subjects: 40
Study 9489975 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (192 U/ml, 1920 U/ml, 19,200 U/ml)
Number of subjects: 12
Study 9489975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator (120 U/ml, 1200 U/ml, 12,000 U/ml)
Number of subjects: 12
Study 9489975 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (160 mg/day)
Number of subjects: 12
Study 9489975 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (660 mg/day)
Number of subjects: 12
Study 7838915 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (15 mg) with vigilance activity
Number of subjects: 8
Study 7838915 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam (0.25 mg) with relaxation activity
Number of subjects: 8
Study 7838915 — intervention group
Group type: COMPARATOR
Intervention: placebo with vigilance activity
Number of subjects: 8
Study 7838915 — intervention group
Group type: COMPARATOR
Intervention: placebo with relaxation activity
Number of subjects: 8
Study 7838915 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (15 mg) with relaxation activity
Number of subjects: 8
Study 7838915 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam (0.25 mg) with vigilance activity
Number of subjects: 8
Study 3169214 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (high dose, 1,000 and 1,200 micrograms per day)
Number of subjects: 31
Study 3169214 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms per day)
Number of subjects: 31
Study 3169214 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone (high dose, 1,000 and 1,200 micrograms per day)
Number of subjects: 31
Study 3169214 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone (800 micrograms per day)
Number of subjects: 31
Study 3169214 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 31
Study 3169214 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone
Number of subjects: 31
Study 12207833 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach meals with a mono:polyglutamate ratio 40:60
Number of subjects: 11
Study 12207833 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach meals
Number of subjects: 11
Study 12207833 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplement
Number of subjects: 11
Study 30762945 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (median dose after 50 min 0.09 (range 0-0.26) μg kg-1 min-1)
Number of subjects: 24
Study 30762945 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care, NA administered only if MAP decreased below 60 mmHg)
Number of subjects: 24
Study 30340488 — intervention group
Group type: EXPERIMENTAL
Intervention: QUEST tool
Number of subjects: 45
Study 30340488 — intervention group
Group type: COMPARATOR
Intervention: Existing tools
Number of subjects: 45
Study 27806634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 52
Study 27806634 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 52
Study 24872552 — intervention group
Group type: EXPERIMENTAL
Intervention: Global similarity among activation patterns in the medial temporal lobes (MTLs)
Number of subjects: 0
Study 23122534 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen sublingual tablet
Number of subjects: 473
Study 23122534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 20040526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks, followed by 125 mg twice daily for 12 weeks
Number of subjects: 17
Study 20040526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20040526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 17
Study 18807726 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening‐EA
Number of subjects: 60
Study 18807726 — intervention group
Group type: COMPARATOR
Intervention: Morning‐EA
Number of subjects: 60
Study 16005336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 294
Study 16005336 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Acupuncture
Number of subjects: 294
Study 16005336 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 294
Study 16005336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture
Number of subjects: 294
Study 16005336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Waiting List
Number of subjects: 294
Study 16005336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture after 52 weeks
Number of subjects: 294
Study 11901542 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccines derived from tumor antigens
Number of subjects: 0
Study 10352750 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide treatment (daily dosage of 470 +/- 160 micrograms for 16.5 +/- 10 weeks)
Number of subjects: 24
Study 10352750 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 24
Study 10352750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Octreotide treatment)
Number of subjects: 24